MedTrace Logo

Towards Optimal Treatment for High Risk Prostate Cancer

NCT06204341 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2024-09-19

No results posted yet for this study

Summary

The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.

* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation)
* the tumor will get a higher dose
* androgen deprivation therapy will be reduced as much al possible preventing side effects

Researchers will compare oncological outcome and toxicity.

Conditions

  • High Risk Prostate Carcinoma

Interventions

RADIATION

HYPOPRIME treatment

Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy

Sponsors & Collaborators

  • Tata Memorial Centre

    collaborator OTHER

  • Haaglanden Medical Centre

    lead OTHER

Principal Investigators

  • Leonard P Bokhorst, MD, PhD · Haaglanden Medical Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2032-12-18
Completion
2032-12-18

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204341 on ClinicalTrials.gov